(64 days)
No
The summary describes a mechanical fixation system and does not mention any AI or ML components or functionalities.
Yes
The device is intended to provide fixation and promote healing following a syndesmotic trauma, which aligns with the definition of a therapeutic device designed to treat or alleviate a medical condition.
No
The device is an implantable system designed for fixation during the healing process following syndesmotic trauma, not for determining the presence or nature of a disease or condition.
No
The device description explicitly states that the system comprises a permanent implantable Tube-Tape and titanium alloy Button, along with disposable hardware components (drill bit, guidewire, coracoid passer). This indicates it is a hardware-based medical device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for providing fixation during the healing process following trauma and as an adjunct in external and intramedullary fixation systems. This is a therapeutic and structural function within the body.
- Device Description: The device is described as a permanent implantable system (Tube-Tape and Button) and disposable surgical tools (drill bit and guidewire). These are physical components used in a surgical procedure.
- Lack of Diagnostic Function: There is no mention of the device being used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
IVD devices are used to perform tests on samples like blood, urine, or tissue to diagnose diseases or conditions. This device is a surgical implant and tool used for mechanical support and fixation within the body.
N/A
Intended Use / Indications for Use
The Infinity-Lock™ Button System is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruption and as an adjunct in external and intramedullary fixation systems involving plates.
The Infinity-Lock™ Button System is indicated for patients with acromioclavicular separations resulting from disruption to the coracoclavicular ligaments.
Product codes (comma separated list FDA assigned to the subject device)
HTN
Device Description
The Infinity-Lock™ Button System comprises a permanent implantable 240 mm Tube-Tape and titanium alloy Button together with a disposable cannulated drill bit and guidewire. A coracoid passer, such as the Xiros CCHook, is also required.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
syndesmotic trauma, acromioclavicular separations, clavicle
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The Infinity-Lock™ Button System was tested against the AC TightRope™ Repair Kit Titanium (K052776) for Ultimate tensile strength (UTS), UTS after fatiguing and extension affer fatiguing. The results were not statistically significantly different, leading to the determination of substantial equivalence. Pyrogenicity testing was carried out using LAL testing via the Gel Clot method, and a pass result of
§ 888.3030 Single/multiple component metallic bone fixation appliances and accessories.
(a)
Identification. Single/multiple component metallic bone fixation appliances and accessories are devices intended to be implanted consisting of one or more metallic components and their metallic fasteners. The devices contain a plate, a nail/plate combination, or a blade/plate combination that are made of alloys, such as cobalt-chromium-molybdenum, stainless steel, and titanium, that are intended to be held in position with fasteners, such as screws and nails, or bolts, nuts, and washers. These devices are used for fixation of fractures of the proximal or distal end of long bones, such as intracapsular, intertrochanteric, intercervical, supracondylar, or condylar fractures of the femur; for fusion of a joint; or for surgical procedures that involve cutting a bone. The devices may be implanted or attached through the skin so that a pulling force (traction) may be applied to the skeletal system.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains two logos. The logo on the left is the Department of Health & Human Services - USA logo. The logo on the right is the FDA U.S. Food & Drug Administration logo. The FDA logo is in blue.
April 3, 2018
Xiros Ltd Stephen Seed Compliance Director Springfield House, Whitehouse Lane Leeds, West Yorkshire LS19 7UE United Kingdom
Re: K180243
Trade/Device Name: Infinity-Lock™ Button System Regulation Number: 21 CFR 888.3030 Regulation Name: Single/multiple component metallic bone fixation appliances and accessories Regulatory Class: Class II Product Code: HTN Dated: January 26, 2018 Received: January 29, 2018
Dear Mr. Seed:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good
1
manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K180243
Device Name
Infinity-LockTM Button System
Indications for Use (Describe)
The Infinity-Lock™ Button System is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruption and as an adjunct in external and intramedullary fixation systems involving plates.
The Infinity-Lock™ Button System is indicated for patients with acromioclavicular separations resulting from disruption to the coracoclavicular ligaments.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and comblete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the word "XIROS" in a rounded, gray box. The box has rounded corners and a thick gray outline. A thin gray line extends from the upper right corner of the box, suggesting a connection or continuation to something outside the frame. The text "XIROS" is in a bold, sans-serif font and is centered within the box.
510(k) Summary
In accordance with 21 CFR 807.92, the following information constitutes Xiros Ltd. 510(k) summary for the Infinity-Lock™ Button System.
I. SUBMITTER INFORMATION
| Submitter`s Name: | Xiros Limited |
|---|---|
| Address: | Springfield House |
| Whitehouse Lane | |
| Leeds LS19 7UE | |
| United Kingdom | |
| Telephone Number: | +44 (0)1132387200 |
| Fax Number: | +44 (0)113 2387201 |
| Contact Person: | Stephen Seed (Compliance Director) |
| Date: | 26 January 2018 |
| 510(k) document number: | K180243 |
II. DEVICE IDENTIFICATION
| Name of Device: | Infinity-Lock™ Button System |
|---|---|
| Trade Name: | Infinity-Lock™ Button System |
| Common or usual name: | Button/suture |
| Classification Name: | Washer, bolt nut |
| Regulatory Class: | Class II |
| Product Code: | HTN |
| Regulation: | 888.3030 |
| Panel: | Orthopedic |
4
Image /page/4/Picture/0 description: The image shows the word "XIROS" in gray, set against a white background. The word is enclosed in a gray, rounded rectangle. A gray line extends from the right side of the rectangle, curving slightly upwards.
III. PREDICATE DEVICE
AC TightRope™ Repair Kit Titanium (AR-2257) manufactured by Arthrex Inc, K052776. This predicate has not been subject to a design related recall.
Reference device 1. for fixation at the clavicle for essentially the same indications for use; Lockdown™ Acromioclavicular (AC) device, manufactured by Surgicraft (Trading name of Mandaco 569 Limited), K091207.
Reference device 2. for materials in Tube-Tape within the very general scope of the reference device intended use for soft tissue approximation: Infinity-Lock 3, Infinity-Lock 5, manufactured by Xiros Limited, K171680.
Reference device 3. for materials in Button for different intended purpose: SECURE-LOOP, manufactured by Xiros Limited, K151601.
IV. DEVICE DESCRIPTION
The Infinity-Lock™ Button System comprises a permanent implantable 240 mm Tube-Tape and titanium alloy Button together with a disposable cannulated drill bit and guidewire. A coracoid passer, such as the Xiros CCHook, is also required.
V. INDICATIONS FOR USE
The Infinity-Lock™ Button System is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruption and as an adjunct in external and intramedullary fixation systems involving plates.
The Infinity-Lock™ Button System is indicated for patients with acromioclavicular separations resulting from disruption to the coracoclavicular ligaments.
VI. COMPARISIONS OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The Infinity-Lock™ Button System has the same technological characteristics as the predicate device, with respect to intended use (the subject device falls within the scope of the predicate device), labelling, anatomical site, similar basic design consisting of titanium buttons and polymeric sutures and a similar surgical technique using mechanical means to reduce the clavicle to the required position.
5
Image /page/5/Picture/0 description: The image contains a gray rounded rectangle with the word "XIROS" in bold, gray letters inside. The rectangle has a small extension at the top, giving it a slightly stylized appearance. The background is plain and white.
VII. PERFORMANCE DATA
The Infinity-Lock™ Button System when tested against the AC TightRope™ Repair Kit Titanium (K052776) for Ultimate tensile strength (UTS), UTS after fatiguing and extension affer fatiguing, was not statistically significantly different and determined to be substantially equivalent. Pyrogenicity testing was carried out using LAL testing via the Gel Clot method and a pass result of